GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Shares Outstanding (EOP)

Humanigen (Humanigen) Shares Outstanding (EOP) : 119.08 Mil (As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Humanigen Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Humanigen's shares outstanding for the quarter that ended in Mar. 2023 was 119.08 Mil.

Humanigen's quarterly shares outstanding stayed the same from Dec. 2022 (119.08 Mil) to Mar. 2023 (119.08 Mil).

Humanigen's annual shares outstanding increased from Dec. 2021 (64.03 Mil) to Dec. 2022 (119.08 Mil). It means Humanigen issued new shares from Dec. 2021 to Dec. 2022 .


Humanigen Shares Outstanding (EOP) Historical Data

The historical data trend for Humanigen's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Shares Outstanding (EOP) Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.97 22.81 51.63 64.03 119.08

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.95 71.24 119.08 119.08 119.08

Competitive Comparison of Humanigen's Shares Outstanding (EOP)

For the Biotechnology subindustry, Humanigen's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humanigen's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Humanigen's Shares Outstanding (EOP) falls into.



Humanigen Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Humanigen  (OTCPK:HGENQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Humanigen Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Humanigen's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen (Humanigen) Business Description

Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
Dale Chappell 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne officer: Chief Medical Officer 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant director 90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan officer: Chief Commercial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie director C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd. 10 percent owner C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd. 10 percent owner C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton director 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd. 10 percent owner P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester officer: Chief Financial Officer C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022

Humanigen (Humanigen) Headlines

From GuruFocus